Cargando…

Comparison of the clinical characteristics and comprehensive assessments of the 2011 and 2017 GOLD classifications for patients with COPD in China

OBJECTIVE: Compared with the 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD), there have been significant changes in the 2017 GOLD classification. The purpose of this study was to analyze the changes in clinical characteristics of the new A-B-C-D system and to explore its role in...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yu-He, Liang, Zhen-Yu, Xu, Li-Mei, Xu, Wen-Hui, Liao, Hao, Li, Rui, Wang, Kai, Xu, Ying, Ou, Chun-Quan, Chen, Xin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167996/
https://www.ncbi.nlm.nih.gov/pubmed/30319249
http://dx.doi.org/10.2147/COPD.S174668
_version_ 1783360300327632896
author Hu, Yu-He
Liang, Zhen-Yu
Xu, Li-Mei
Xu, Wen-Hui
Liao, Hao
Li, Rui
Wang, Kai
Xu, Ying
Ou, Chun-Quan
Chen, Xin
author_facet Hu, Yu-He
Liang, Zhen-Yu
Xu, Li-Mei
Xu, Wen-Hui
Liao, Hao
Li, Rui
Wang, Kai
Xu, Ying
Ou, Chun-Quan
Chen, Xin
author_sort Hu, Yu-He
collection PubMed
description OBJECTIVE: Compared with the 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD), there have been significant changes in the 2017 GOLD classification. The purpose of this study was to analyze the changes in clinical characteristics of the new A-B-C-D system and to explore its role in comprehensive assessment of COPD. SUBJECTS AND METHODS: A total of 631 stable COPD patients were included in a cross-sectional survey. Data collected included baseline data and pulmonary function testing results, respiratory muscle strength, symptoms and quality of life, exercise capacity, nutritional status, and anxiety and depression as a comprehensive assessment. Based on the 2011 GOLD and 2017 GOLD classifications, patients were divided into Groups A(1)–D(1) and Groups A(2)–D(2), respectively. RESULTS: In the 2011 GOLD, 64 subjects in Group C(1) were reclassified into Group A(2) (41.6%), while 77 subjects in Group D(1) were reclassified into Group B(2) (27.1%). The old and new grading systems were somewhat consistent (Cohen’s kappa=0.6963, P<0.001). Lung function was lower, while the body mass index, airflow obstruction, dyspnea, and exercise capacity index (BODE index) was higher in Group A(2) than in Group A(1) (P<0.001). In Group B(2), lung function, 6-minute walking distance (6MWD), and respiratory muscle strength were significantly lower than in Group B(1) (P<0.001), while the BODE index (P<0.001) was higher. In comprehensive assessment, subjects in Groups B(2) and D(2) had significantly lower lung function, 6MWD, respiratory muscle strength, quality of life, higher symptom scores, and BODE index than subjects in Group A(2) (P<0.001). The differences between Group A(2) and C(2) were small. CONCLUSION: Compared with the 2011 GOLD, the 2017 GOLD reclassified more patients into Groups A and B, those with significantly worse lung function and higher BODE index. In the comprehensive assessment of the new classification, Groups B and D may have greater disease severity. However, the effectiveness of the new grading system in predicting patient prognosis, and its guidance on the use of drugs, remains to be explored in future studies.
format Online
Article
Text
id pubmed-6167996
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61679962018-10-12 Comparison of the clinical characteristics and comprehensive assessments of the 2011 and 2017 GOLD classifications for patients with COPD in China Hu, Yu-He Liang, Zhen-Yu Xu, Li-Mei Xu, Wen-Hui Liao, Hao Li, Rui Wang, Kai Xu, Ying Ou, Chun-Quan Chen, Xin Int J Chron Obstruct Pulmon Dis Original Research OBJECTIVE: Compared with the 2011 Global Initiative for Chronic Obstructive Lung Disease (GOLD), there have been significant changes in the 2017 GOLD classification. The purpose of this study was to analyze the changes in clinical characteristics of the new A-B-C-D system and to explore its role in comprehensive assessment of COPD. SUBJECTS AND METHODS: A total of 631 stable COPD patients were included in a cross-sectional survey. Data collected included baseline data and pulmonary function testing results, respiratory muscle strength, symptoms and quality of life, exercise capacity, nutritional status, and anxiety and depression as a comprehensive assessment. Based on the 2011 GOLD and 2017 GOLD classifications, patients were divided into Groups A(1)–D(1) and Groups A(2)–D(2), respectively. RESULTS: In the 2011 GOLD, 64 subjects in Group C(1) were reclassified into Group A(2) (41.6%), while 77 subjects in Group D(1) were reclassified into Group B(2) (27.1%). The old and new grading systems were somewhat consistent (Cohen’s kappa=0.6963, P<0.001). Lung function was lower, while the body mass index, airflow obstruction, dyspnea, and exercise capacity index (BODE index) was higher in Group A(2) than in Group A(1) (P<0.001). In Group B(2), lung function, 6-minute walking distance (6MWD), and respiratory muscle strength were significantly lower than in Group B(1) (P<0.001), while the BODE index (P<0.001) was higher. In comprehensive assessment, subjects in Groups B(2) and D(2) had significantly lower lung function, 6MWD, respiratory muscle strength, quality of life, higher symptom scores, and BODE index than subjects in Group A(2) (P<0.001). The differences between Group A(2) and C(2) were small. CONCLUSION: Compared with the 2011 GOLD, the 2017 GOLD reclassified more patients into Groups A and B, those with significantly worse lung function and higher BODE index. In the comprehensive assessment of the new classification, Groups B and D may have greater disease severity. However, the effectiveness of the new grading system in predicting patient prognosis, and its guidance on the use of drugs, remains to be explored in future studies. Dove Medical Press 2018-09-28 /pmc/articles/PMC6167996/ /pubmed/30319249 http://dx.doi.org/10.2147/COPD.S174668 Text en © 2018 Hu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Hu, Yu-He
Liang, Zhen-Yu
Xu, Li-Mei
Xu, Wen-Hui
Liao, Hao
Li, Rui
Wang, Kai
Xu, Ying
Ou, Chun-Quan
Chen, Xin
Comparison of the clinical characteristics and comprehensive assessments of the 2011 and 2017 GOLD classifications for patients with COPD in China
title Comparison of the clinical characteristics and comprehensive assessments of the 2011 and 2017 GOLD classifications for patients with COPD in China
title_full Comparison of the clinical characteristics and comprehensive assessments of the 2011 and 2017 GOLD classifications for patients with COPD in China
title_fullStr Comparison of the clinical characteristics and comprehensive assessments of the 2011 and 2017 GOLD classifications for patients with COPD in China
title_full_unstemmed Comparison of the clinical characteristics and comprehensive assessments of the 2011 and 2017 GOLD classifications for patients with COPD in China
title_short Comparison of the clinical characteristics and comprehensive assessments of the 2011 and 2017 GOLD classifications for patients with COPD in China
title_sort comparison of the clinical characteristics and comprehensive assessments of the 2011 and 2017 gold classifications for patients with copd in china
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167996/
https://www.ncbi.nlm.nih.gov/pubmed/30319249
http://dx.doi.org/10.2147/COPD.S174668
work_keys_str_mv AT huyuhe comparisonoftheclinicalcharacteristicsandcomprehensiveassessmentsofthe2011and2017goldclassificationsforpatientswithcopdinchina
AT liangzhenyu comparisonoftheclinicalcharacteristicsandcomprehensiveassessmentsofthe2011and2017goldclassificationsforpatientswithcopdinchina
AT xulimei comparisonoftheclinicalcharacteristicsandcomprehensiveassessmentsofthe2011and2017goldclassificationsforpatientswithcopdinchina
AT xuwenhui comparisonoftheclinicalcharacteristicsandcomprehensiveassessmentsofthe2011and2017goldclassificationsforpatientswithcopdinchina
AT liaohao comparisonoftheclinicalcharacteristicsandcomprehensiveassessmentsofthe2011and2017goldclassificationsforpatientswithcopdinchina
AT lirui comparisonoftheclinicalcharacteristicsandcomprehensiveassessmentsofthe2011and2017goldclassificationsforpatientswithcopdinchina
AT wangkai comparisonoftheclinicalcharacteristicsandcomprehensiveassessmentsofthe2011and2017goldclassificationsforpatientswithcopdinchina
AT xuying comparisonoftheclinicalcharacteristicsandcomprehensiveassessmentsofthe2011and2017goldclassificationsforpatientswithcopdinchina
AT ouchunquan comparisonoftheclinicalcharacteristicsandcomprehensiveassessmentsofthe2011and2017goldclassificationsforpatientswithcopdinchina
AT chenxin comparisonoftheclinicalcharacteristicsandcomprehensiveassessmentsofthe2011and2017goldclassificationsforpatientswithcopdinchina